Research in Blood Advances proposes shortening CAR-T therapy monitoring period from four weeks to two weeks, as severe side effects peak within the first two weeks.
New research in Blood Advances suggests reducing the monitoring period for CAR-T therapy patients from four weeks to two weeks, as the risk of severe side effects, cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, peak within the first two weeks after therapy. This change could improve accessibility for disadvantaged patients, save resources for treatment centers, and allow patients to resume normal life sooner.
July 24, 2024
3 Articles